Contact: Michelle Mechaley - Marketing Manager 
Telephone: (518) 798-1215, Ext. 341
Email: mmechaley@angiodynamics.com

DR. THOMAS SOS PRESENTING AT THE TCT 2002 CONFERENCE

Westbury, New York, August 6, 2002 Queensbury, NY; September 24, 2002 - AngioDynamics, Inc., 
a wholly-owned subsidiary of E-Z-EM, Inc., (AMEX: EZM.A and EZM.B) announced today that 
Dr. Thomas Sos, Professor and Vice Chairman of Radiology and Past Chief of Interventional 
Radiology of New York Presbyterian Hospital, will be presenting on the Feasibility of MRA 
with a MR transparent stent, the AngioDynamics Biliary OmniFlexä 15mm Platinum Stent at the 
Transcatheter Cardiovascular Therapeutics (TCT) 2002 conference in Washington, DC. In 
addition, Dr. Sos will also be presenting on September 27th on the "Top 10 Tips for Renal 
Stenting".

The OMNIFLEX(TM) 15MM BILIARY STENT is Magnetic Resonance Angiography (MRA) compatible due 
to its platinum material and design characteristics. The platinum OMNIFLEX(TM) is 
nonferromagnetic, which has been shown to produce significantly less artifacts than 
stainless steel or nitinol stents during MRA procedures. Artifacts can reduce the visibility 
of the lumen and make accurate assessment of the patency of that lumen more difficult.

Commenting on the announcement, Eamonn P. Hobbs, President/CEO of AngioDynamics, said, 
"AngioDynamics is pleased to have such a well respected expert in his field present on his 
clinical experience with the AngioDynamics Stent at this international conference."


--------------------------------------------------------------------------------
The statements made in this document contain certain forward-looking statements that involve 
a number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans",
"believes", "seeks", "estimates," or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the 
FDA or other regulatory agencies, results of pending or future clinical trials, overall 
economic conditions, general market conditions, foreign currency exchange rate fluctuations, 
the effects on pricing from Group Purchasing Organizations, competition, including alternative 
procedures which continue to replace traditional fluoroscopic procedures, as well as the risk 
factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited 
to its Form 10-Q for the quarter ended March 2, 2002, as well as its Annual Report on Form 10_K 
for the year ended June 2, 2001, may affect the actual results achieved by the Company. 
  
End